Royalty Pharma Shares Dip After-Hours Following Drug Trial Failure

New York, Sunday, 6 September 2026.
Despite strong yearly returns, Royalty Pharma stock fell over 5% after-hours on September 4, 2026, following news that Novartis’s Phase 3 cardiovascular trial for pelacarsen failed.